JP2005519949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519949A5 JP2005519949A5 JP2003574615A JP2003574615A JP2005519949A5 JP 2005519949 A5 JP2005519949 A5 JP 2005519949A5 JP 2003574615 A JP2003574615 A JP 2003574615A JP 2003574615 A JP2003574615 A JP 2003574615A JP 2005519949 A5 JP2005519949 A5 JP 2005519949A5
- Authority
- JP
- Japan
- Prior art keywords
- nateglinide
- salt
- nateglinide according
- group
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960000698 nateglinide Drugs 0.000 claims description 25
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- -1 nateglinide anion Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36317802P | 2002-03-11 | 2002-03-11 | |
| PCT/EP2003/002447 WO2003076393A1 (en) | 2002-03-11 | 2003-03-10 | Salts of nateglinide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010214827A Division JP2011006476A (ja) | 2002-03-11 | 2010-09-27 | ナテグリニドの塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519949A JP2005519949A (ja) | 2005-07-07 |
| JP2005519949A5 true JP2005519949A5 (https=) | 2006-10-26 |
Family
ID=27805267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574615A Withdrawn JP2005519949A (ja) | 2002-03-11 | 2003-03-10 | ナテグリニドの塩 |
| JP2010214827A Pending JP2011006476A (ja) | 2002-03-11 | 2010-09-27 | ナテグリニドの塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010214827A Pending JP2011006476A (ja) | 2002-03-11 | 2010-09-27 | ナテグリニドの塩 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050234129A1 (https=) |
| EP (1) | EP1483232A1 (https=) |
| JP (2) | JP2005519949A (https=) |
| CN (1) | CN1274668C (https=) |
| AR (1) | AR038927A1 (https=) |
| AU (1) | AU2003214112A1 (https=) |
| BR (1) | BR0308316A (https=) |
| CA (1) | CA2478599A1 (https=) |
| PE (1) | PE20040158A1 (https=) |
| TW (1) | TW200304813A (https=) |
| WO (1) | WO2003076393A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7449519B2 (en) * | 2003-02-18 | 2008-11-11 | Konishi Co., Ltd. | Curing resin, method for producing same and curing resin composition |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| HU227073B1 (hu) * | 2003-07-10 | 2010-06-28 | Richter Gedeon Nyrt | Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| WO2005016315A1 (en) * | 2003-08-14 | 2005-02-24 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler |
| WO2005020979A1 (en) * | 2003-09-03 | 2005-03-10 | Ranbaxy Laboratories Limited | A process for the preparation of pharmaceutical compositions of nateglinide |
| TWI340650B (en) | 2004-01-21 | 2011-04-21 | Otsuka Pharma Co Ltd | Amine saly of carbostyril derivative |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| EP2305239A1 (fr) * | 2009-09-24 | 2011-04-06 | Assistance Publique, Hopitaux De Paris | Neuroprotection retinienne par des inhibiteurs des canaux ioniques regules par la sous-unite SUR |
| EP3003327B1 (en) | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| CN103417971A (zh) * | 2013-08-13 | 2013-12-04 | 深圳奥萨医药有限公司 | 二肽基肽酶抑制剂和b族维生素的药物组合物及用途 |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| ES2100291T3 (es) * | 1991-07-30 | 1997-06-16 | Ajinomoto Kk | Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos. |
| WO2000059865A1 (en) * | 1999-04-06 | 2000-10-12 | Ono Pharmaceutical Co., Ltd. | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient |
| CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| AU1133901A (en) * | 1999-10-08 | 2001-04-23 | Novartis Ag | Method of treating metabolic disorders |
| HUP0600522A2 (en) * | 1999-12-23 | 2006-11-28 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
| PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
-
2003
- 2003-03-10 CA CA002478599A patent/CA2478599A1/en not_active Abandoned
- 2003-03-10 WO PCT/EP2003/002447 patent/WO2003076393A1/en not_active Ceased
- 2003-03-10 EP EP03709769A patent/EP1483232A1/en not_active Withdrawn
- 2003-03-10 JP JP2003574615A patent/JP2005519949A/ja not_active Withdrawn
- 2003-03-10 BR BR0308316-0A patent/BR0308316A/pt not_active IP Right Cessation
- 2003-03-10 AU AU2003214112A patent/AU2003214112A1/en not_active Abandoned
- 2003-03-10 US US10/507,255 patent/US20050234129A1/en not_active Abandoned
- 2003-03-10 TW TW092105092A patent/TW200304813A/zh unknown
- 2003-03-10 CN CNB038058030A patent/CN1274668C/zh not_active Expired - Lifetime
- 2003-03-11 AR ARP030100828A patent/AR038927A1/es unknown
- 2003-03-11 PE PE2003000246A patent/PE20040158A1/es not_active Application Discontinuation
-
2009
- 2009-02-06 US US12/366,936 patent/US20090143469A1/en not_active Abandoned
-
2010
- 2010-09-27 JP JP2010214827A patent/JP2011006476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519949A5 (https=) | ||
| AU2023200826B2 (en) | Administration of berberine metabolites | |
| KR102795284B1 (ko) | 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법 | |
| KR950002150B1 (ko) | 레보도파 메틸에스테르를 함유하는 제약 조성물 | |
| DE69710390T2 (de) | Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| RU2007116869A (ru) | Комбинация органических соединений | |
| JPH0717501B2 (ja) | 高めた無痛覚を与える製薬製品 | |
| JP2005537268A5 (https=) | ||
| CN109414454A (zh) | 用于癌症治疗的组合疗法 | |
| JP2005523898A5 (ja) | 運動障害治療剤 | |
| Rose et al. | The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets | |
| DE10054278A1 (de) | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose | |
| CN110279866B (zh) | 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品 | |
| JPS6143117A (ja) | ピリミド‐ピリミジンおよびｏ‐アセチルサリチル酸からなる組合せ生成物 | |
| RU2007114297A (ru) | Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения | |
| JPH07116048B2 (ja) | パーキンソン症候群の治療用薬剤 | |
| RU2367427C1 (ru) | Литийсодержащее средство для профилактики и лечения цереброваскулярных заболеваний и способ применения данного средства | |
| EP3212177A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| DE60033830T2 (de) | Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält | |
| CN100506224C (zh) | 包含选择性环加氧酶-2抑制剂的组合 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP4648193B2 (ja) | 医薬組成物 | |
| JP2022540198A (ja) | 組合せ | |
| JP7527662B2 (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 |